leadf
logo-loader
viewArix Bioscience PLC

Arix Biosciences notes new data from Autolus on lymphona treatment  

“The data support a best in class profile with a high level of complete remissions and a well-tolerated safety profile”

Arix Bioscience PLC -

Arix Bioscience PLC (LON:ARIX) has noted new data has been published by portfolio company Autolus Therapeutics PLC (NADSDAQ:AUTL).

The release highlights progress on AUTO3, a CAR T cell therapy being investigated in a Phase 1/2 clinical trial in relapsed/refractory diffuse large B cell lymphoma (DLBCL), a cancer that starts in white blood cells.

“The data support a best in class profile with a high level of complete remissions and a well tolerated safety profile,” said Dr. Christian Itin, chairman and chief executive officer of Autolus.

“AUTO3 has a tolerable and very favorable safety profile when compared with approved CD19 CAR T therapies,” added Dr Craig Moskowitz, Professor of Medicine at Miller School of Medicine, University of Miami Health System.

“It has a promising complete response rate of 64%, as demonstrated in the completed cohorts at the recommended Phase 2 dose range and, thus far, these complete remissions also appear durable.

Autolus issued the data at the European Society for Medical Oncology (ESMO) Virtual Congress 2020 that started on 18 September.

DLBCL is the most common form of non-Hodgkin lymphoma among adults.

Quick facts: Arix Bioscience PLC

Price: 105.5 GBX

LSE:ARIX
Market: LSE
Market Cap: £143.12 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Arix Bioscience PLC named herein, including the promotion by the Company of Arix Bioscience PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Market report: FTSE flounders as imminent Brexit talks loom

The FTSE is mixed this Tuesday despite the weaker pound. Sterling is still battling no deal Brexit fears as the UK Prime Minister Boris Johnson threatens that if no progress on the talks with the EU is made week, preparations for a no deal will be ramped up. Britain’s biggest sports retailer...

on 8/9/20

2 min read